Integra LifeSciences Holdings Corporation — 2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017. The filing is an annual report, not a standalone Q4 filing; fourth-quarter results are provided in unaudited quarterly information. Integra is a global medical technology company operating in Codman Specialty Surgical and Orthopedics and Tissue Technologies, with approximately 4,400 employees and sales in more than 130 countries.
Business Context
- Products address neurosurgery, neuro-critical care, surgical instruments, regenerative technologies, wound care, extremity orthopedics, nerve and tendon repair, and small-joint reconstruction.
- 2017 strategy emphasized execution, scale, innovation and customer excellence, supported by acquisitions, portfolio optimization, commercial-channel investment and new product introductions.
- Major 2017 acquisitions included Codman Neurosurgery from Johnson & Johnson, Derma Sciences and TGX Medical. Integra also divested certain neurosurgical products to Natus to address antitrust requirements.
Key Financial Metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | $1,188.2 million | $992.1 million | Up 20% |
| Gross margin | $752.7 million | $643.0 million | Up 17% |
| Gross margin percentage | 63.3% | 64.8% | Down 150 basis points |
| Operating income | $44.8 million | $115.3 million | Down 61% |
| Income from continuing operations | $64.7 million | $74.6 million | Down 13% |
| Diluted EPS from continuing operations | $0.82 | $0.94 | Down 13% |
| Operating cash flow | $114.5 million | $116.4 million | Down 2% |
- Codman Specialty Surgical revenue was $720.3 million, up 14%, including $76.9 million from Codman Neurosurgery after its October 2017 acquisition.
- Orthopedics and Tissue Technologies revenue was $467.9 million, up 30%, including $84.6 million from Derma Sciences.
- U.S. revenue was $894.3 million, or 75% of total revenue. International revenue was $293.9 million; foreign exchange increased revenue by $2.4 million.
- Fourth-quarter revenue was $368.6 million, gross margin was $220.4 million and net income was $44.4 million. Fourth-quarter earnings included a $43.4 million tax benefit from deferred-tax remeasurement and a $2.6 million gain on the Natus divestiture.
- Total special charges were $132.1 million, including $117.9 million of acquisition-related charges, $7.3 million of structural optimization charges, $2.8 million of Hurricane Maria costs and $2.8 million of ERP implementation costs.
- Year-end cash and cash equivalents were $174.9 million, compared with $102.1 million in 2016. Working capital was $473.2 million.
- Total debt under the Senior Credit Facility was approximately $1.9 billion, consisting of $655.0 million under the revolver, $500.0 million under Term Loan A and $700.0 million under Term Loan A-1. Approximately $344.4 million remained available.
- Total assets increased to $3.21 billion, including $937.9 million of goodwill and $1.16 billion of intangible assets. Stockholders’ equity was $962.3 million.
Material Changes Versus the Prior Comparable Period
- Revenue growth was primarily acquisition-driven, supplemented by organic growth across regenerative technologies, instruments, neurosurgery, extremities and private-label products.
- Gross margin declined because acquired Derma Sciences and Codman products carried lower margins than Integra’s historical average, and because of purchase-accounting inventory adjustments and higher amortization.
- Operating income declined substantially as selling, general and administrative expense increased 37% to $624.1 million, driven by acquisition and integration costs, additional sales personnel, commissions and compensation.
- Interest expense increased to $35.0 million from $25.8 million as borrowings increased to fund acquisitions.
- Operating cash flow was broadly stable, but accounts receivable used $89.7 million of cash and investing cash outflows increased to $1.22 billion, primarily for acquisitions.
- Net income benefited from a $43.4 million deferred-tax remeasurement benefit under the Tax Cuts and Jobs Act, partially offset by a $5.5 million estimated one-time repatriation tax.
Guidance, Outlook and Management Commentary
- Management expected 2018 gross margin of approximately 62% to 63%, broadly in line with 2017.
- 2018 research and development expense was expected to be approximately 6.0% of revenue; reported selling, general and administrative expense was expected to be approximately 47% to 48% of revenue.
- 2018 capital expenditures were expected to be $65 million to $75 million, primarily for plant maintenance and automation, orthopedic instrument kits and the Mansfield, Massachusetts facility supporting Codman products.
- Management estimated a 2018 worldwide effective tax rate of approximately 8% to 10%, subject to tax-law developments and completion of the provisional Tax Cuts and Jobs Act accounting.
- Integration of Codman Neurosurgery and Derma Sciences, manufacturing transfers, ERP implementation and infrastructure optimization were identified as continuing priorities.
- Management stated that available cash, operating cash flow and credit capacity were expected to satisfy foreseeable working-capital, debt-repayment and capital-expenditure requirements for at least the following twelve months.
Risks, Contingencies and Unusual Items
- Regulatory risk: The FDA maintained its position that certain BioD morselized amniotic membrane products may require a biologics license rather than regulation solely under Section 361. 2017 revenue from those products was less than 1% of consolidated revenue, but enforcement action could affect sales.
- Acquisition and leverage risk: The company incurred substantial acquisition-related costs and ended 2017 with approximately $1.9 billion of debt. Term-loan principal repayments begin in 2018, and the revolver and remaining term loans mature in December 2021.
- Margin and impairment risk: Goodwill and intangible assets totaled approximately $2.10 billion. No goodwill impairment was recorded in 2017, but future underperformance, discount-rate changes or product discontinuations could result in material charges.
- Operational risk: Hurricane Maria disrupted Puerto Rico infrastructure, although the Añasco facility sustained relatively minor damage and remained operational. The company also relies on certain sole-source suppliers and third-party manufacturers.
- Litigation and contingent payments: TEI remained involved in ten product-liability cases at December 31, 2017, with insurance and indemnification protections. BioD-related earnouts and other contingent consideration remained subject to estimates and future payments.
- Tax uncertainty: Accounting for several Tax Cuts and Jobs Act effects was provisional at year-end and could change materially after further analysis and tax-return preparation.
- Market risks: The company is exposed to floating interest rates and foreign-currency movements. A 100-basis-point rate change was estimated to affect annual interest expense on unhedged debt by approximately $8.1 million.
- Other risks: Medical-device regulation, reimbursement pressure, competition, cybersecurity, data privacy, product liability, bovine-derived materials and international operations could materially affect results.
Important Facts for Investors to Verify
- Determine the extent to which 2017 revenue growth and future growth depend on Codman Neurosurgery and Derma Sciences versus organic growth.
- Assess whether acquisition-related expenses, lower acquired-product margins and integration costs decline as expected.
- Reconcile debt maturities, interest-rate exposure, leverage-covenant headroom and the company’s ability to fund acquisitions and capital expenditures.
- Monitor the FDA’s position and any enforcement or approval requirements affecting BioD amniotic-tissue products.
- Review the final accounting for the Tax Cuts and Jobs Act, including the deferred-tax remeasurement, repatriation tax and future GILTI treatment.
- Evaluate goodwill and intangible-asset carrying values, particularly after the Codman acquisition and any product discontinuations.
- Track operating cash conversion, accounts receivable growth and working-capital requirements following the acquisitions.
- Confirm the resolution and financial exposure of TEI product-liability matters, BioD litigation and contingent consideration obligations.